Key result
HAART initiation linked to ~5 mmHg/year rise in SBP, driven by PI- and NNRTI-based regimens.
Why the study?
The effects of different antiretroviral regimens on blood pressure in HIV-infected individuals were not well characterized.
Does Highly Active Antiretroviral Therapy (HAART) increase blood pressure in HIV-infected individuals?
Population
286 HIV-infected individuals in a State of Hawaii Department of Health program
Comparison
HAART regimens (PI-containing, NNRTI-containing, NRTI-only) vs untreated controls
Design
Retrospective cohort study
Follow-up
Four consecutive 6-month visits
Authors
Loading...
HAART regimens with PIs or NNRTIs were associated with rising BP; leaves open whether regimen selection influences long-term hypertension risk in HIV.
Cohort (n=286)
Does Highly Active Antiretroviral Therapy (HAART) increase blood pressure in HIV-infected individuals?
p-value: p=0.005
HAART regimens containing protease inhibitors or nonnucleoside reverse transcriptase inhibitors are associated with significant increases in blood pressure in HIV-infected patients, highlighting the need for cardiovascular risk monitoring.
Chow et al. (2003) conducted a cohort in HIV Infection (n=286). Highly Active Antiretroviral Therapy (HAART) vs. untreated controls was evaluated on change in systolic blood pressure (SBP) per year (p=0.005). Initiation of HAART in HIV-infected individuals was associated with an increase in systolic blood pressure of 4.71 mmHg/year (p=0.005), driven by PI- and NNRTI-containing regimens.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: